Alphatec (US:ATEC)2025-10-30 20:23Financial Performance - Total revenue for Q3 2025 reached $197 million, an increase of $46 million or 30% year-over-year[3] - Surgical revenue grew by 31% to $177 million, driven by continued momentum in PTPTM and LTPTM[6] - EOS revenue increased by 29% year-over-year to $20 million, reflecting higher adoption of EOS Insight®[6] - Revenue from products and services for Q3 2025 was $196.5 million, a 30.4% increase from $150.7 million in Q3 2024[35] - Gross profit for Q3 2025 reached $137.3 million, up 33.6% from $102.7 million in Q3 2024, resulting in a gross margin of 69.9%[39] - Adjusted EBITDA for the quarter was $26 million, representing a margin of 13%, an increase of 840 basis points year-over-year[6] - Adjusted EBITDA for Q3 2025 was $26.1 million, with an adjusted EBITDA margin of 13.3%, representing an increase of 840 basis points year-over-year[39] - Non-GAAP adjusted EBITDA for the full year is anticipated to be approximately $91 million, up from a previous expectation of $83 million[7] Cash and Assets - The ending cash balance was $156 million, with $5 million in free cash flow generated during the quarter[3][6] - Cash and cash equivalents increased to $155.7 million from $138.8 million at the end of 2024[37] - Total current assets as of September 30, 2025, were $439.8 million, up from $417.4 million at the end of 2024[37] - Total liabilities decreased to $531.3 million from $613.3 million at the end of 2024[37] Losses and Expenses - Operating loss for Q3 2025 was $15.9 million, an improvement from a loss of $33.7 million in Q3 2024[35] - Net loss for Q3 2025 was $28.6 million, compared to a net loss of $39.6 million in Q3 2024, with a net loss per share of $0.19[39] - Research and development expenses for Q3 2025 were $18.7 million, slightly down from $20.4 million in Q3 2024[35] - Stock-based compensation for Q3 2025 amounted to $16.4 million, compared to $17.5 million in Q3 2024[39] Future Outlook - The company achieved a 26% growth in net new surgeon users, indicating strong future growth potential[6] - Full-year revenue guidance was raised to $760 million, reflecting a 24% growth expectation compared to previous guidance of $742 million[7] - Surgical revenue for the full year is now expected to be $684 million, with EOS revenue projected at $76 million[7] Strategic Focus - The company continues to focus on integrating data and informatics into procedural solutions to enhance spine care[5]